Yang
52 IP cases indexed. Covers patent matters.
Cases Presided Over
52 cases indexed | Page 1 of 2
Berkshire Hathaway Energy Company et al. v.MES, Inc.
The IPR against BirchTech’s patent was terminated for MidAmerican Energy Company after a settlement, while the proceeding remains open for Berkshire Hathaway Energy and PacificCorp.
Berkshire Hathaway Energy Company et al. v.MES, Inc.
The PTAB granted a joint motion to terminate the IPR as to WEC Energy Group after the parties settled their dispute over Patent 10,668,430. The termination does not affect the remaining petitioners, and the proceeding continues against them.
Berkshire Hathaway Energy Company et al. v.MES, Inc.
Berkshire Hathaway Energy and its affiliates settled an IPR against BirchTech, leading the Board to terminate the proceeding for two petitioners while keeping the case open for the remaining parties. The settlement agreement was treated as business‑confidential information.
Xencor, Inc. v.Merus N.V.
Xencor, Inc. successfully petitioned the PTAB to institute an IPR against Merus N.V.'s patent (9358286) concerning heterodimeric Ig-like molecules. The Board found sufficient evidence of unpatentability under 35 U.S.C. §§ 102 and 103, advancing the dispute into the substantive review phase.
Berkshire Hathaway Energy Company et al. v.MES, Inc.
The PTAB institution decision found a reasonable likelihood of prevailing for the Petitioners regarding claims covering flue gas pollutant removal. The Board addressed both anticipation and obviousness grounds, concluding that the combination of prior art references was sufficiently motivated to render the asserted claims unpatentable.
PacifiCorp et al. v.MES, Inc.
The PTAB terminated the IPRs against MidAmerican Energy Company after a settlement with BirchTech, leaving the case open only against PacifiCorp.
PacifiCorp et al. v.MES, Inc.
Utility companies and BirchTech settled multiple IPRs covering power‑grid patents. The Board treated the settlement agreements as confidential and terminated the IPRs as to the settling petitioners, leaving the remaining petitioners in the proceeding.
PacifiCorp et al. v.MES, Inc.
The PTAB denied institution of an IPR for a mercury removal patent (10926218) after the Director remanded the case due to multiple concurrent petitions. The denial was based on following the Director's instruction to prioritize one petition over another.
PacifiCorp et al. v.MES, Inc.
PacifiCorp successfully challenged 26 claims of Birchtech Corp.'s patent (10926218) related to flue gas desulfurization, leading the PTAB to find a reasonable likelihood of prevailing on at least one claim. The Board concluded that combining prior art references was an obvious application of known techniques in mercury removal technology.
PacifiCorp et al. v.MES, Inc.
Energy utilities settled their PTAB disputes with BirchTech, prompting the Board to terminate the IPRs for the settling parties and keep the settlement agreements confidential. Remaining petitioners stay in the proceeding.
PacifiCorp et al. v.MES, Inc.
The Board instituted the IPR petition against Patent No. 10589225, finding a reasonable likelihood of prevailing on multiple grounds. The institution decision addressed complex issues regarding real party in interest and written description support for genus claims related to flue gas treatment.
PacifiCorp et al. v.MES, Inc.
The PTAB granted institution for an IPR challenging claims related to mercury removal from flue gas using activated carbon sorbents. The Board found the Petitioner met a reasonable likelihood of prevailing standard, despite disputes over prior art reduction to practice.
SeaSpine Holdings Corporation et al. v.Jackson, Roger
The PTAB denied an IPR petition filed by SeaSpine Holdings against Roger P. Jackson because the patent owner had disclaimed all challenged claims of U.S. Patent No. 11,399,873 B2.
PacifiCorp et al. v.MES, Inc.
MidAmerican Energy settled its IPR against BirchTech’s ’370 patent, prompting the Board to terminate the case for MidAmerican while the proceeding remains active against PacifiCorp.
PacifiCorp et al. v.MES, Inc.
Utility consortiums including PacifiCorp settled IPRs covering several power‑grid patents, resulting in the termination of the proceeding for two petitioners while the Board kept the case open for the remaining parties. The settlement agreement was designated business‑confidential.
PacifiCorp et al. v.MES, Inc.
The PTAB denied institution of an IPR petition challenging a mercury removal patent (10933370) because the petitioner had filed a second, ranked petition on the same claims. The Board followed the Director's instruction to select only one petition.
PacifiCorp et al. v.MES, Inc.
The PTAB decided to institute the IPR petition against Birchtech Corp.'s '370 patent, finding that PacifiCorp et al. met the standard for reasonable likelihood of prevailing on all asserted grounds. The Board also addressed and rejected arguments from Patent Owner regarding written description and enablement issues concerning bromide compounds.
PacifiCorp et al. v.MES, Inc.
The PTAB instituted IPR on PacifiCorp's claims against Birchtech Corp. regarding flue gas desulfurization technology, overcoming a time-bar defense raised by the Patent Owner. The Board found Petitioner met the reasonable likelihood standard for institution across multiple grounds of anticipation and obviousness.
Padagis US LLC et al. v.Neurelis, Inc.
The PTAB held that all 36 claims of Neurelis’s intranasal benzodiazepine patent are obvious over prior art references Gwozdz, Meezan ’962, and Cartt ’784, rendering the patent entirely unpatentable.
NeoGenomics Laboratories, Inc. v.Natera, Inc.
The PTAB denied NeoGenomics’s petition to institute an IPR against Natera’s 11,530,454 patent covering liquid‑biopsy methods. The Board found the prior art had already been considered and no material error existed. No trial will be held.
Inari Agriculture, Inc. v.Pioneer Hi-Bred International, Inc.
The PTAB denied institution of Inari Agriculture's PGR against Pioneer Hi-Bred International regarding maize breeding claims. The Board found the Petitioner failed to demonstrate a reasonable expectation of success, specifically failing to adequately address the unique genotype (PH4CYJ) central to the patent.
Dr. Falk Pharma GmbH v.Ellodi Pharmaceuticals LP
Dr. Falk Pharma GmbH successfully challenged a pharmaceutical patent (11260061) in an IPR, showing a reasonable likelihood of prevailing on grounds of obviousness (§ 103). The Board's decision hinged on extensive claim construction, particularly defining 'adsorbed onto a pharmaceutically acceptable carrier.'
QIAGEN Sciences, LLC v.Tecan Group AG
Tecan seeks Director Review to overturn the PTAB’s institution of QIAGEN’s IPR, arguing the Board abused discretion, over‑relied on expert testimony, and allowed duplicate petitions. The request targets the institution decision for patent No. 10,036,012 covering NGS genotyping methods.
QIAGEN Sciences, LLC v.Tecan Group AG
QIAGEN Sciences successfully petitioned to institute IPR proceedings against Tecan Genomics, challenging claims of U.S. Patent No. 10876108 based on obviousness (35 U.S.C. § 103). The Board found that the Examiner erred in relying solely on secondary considerations, adopting the Petitioner's view that combining Shapero and Delseny renders multiple claims obvious.
QIAGEN Sciences, LLC v.Tecan Group AG
QIAGEN Sciences successfully petitioned the PTAB against Tecan Genomics regarding claims related to Next-Generation Sequencing (NGS). The Board instituted review, finding a reasonable likelihood of prevailing on obviousness grounds.
QIAGEN Sciences, LLC v.Tecan Group AG
QIAGEN Sciences successfully convinced the PTAB to institute trial proceedings against Tecan Genomics, Inc. regarding a high-throughput sequencing patent (11098357). The Board found reasonable likelihood that claims 1 through 10 are unpatentable under both anticipation (§ 102) and obviousness (§ 103).
Integrated DNA Technologies, Inc. et al. v.Tecan Group AG
Integrated DNA Technologies sought IPR of Tecan Genomics' patent covering nucleic acid technologies. The patent owner filed a terminal disclaimer of the entire patent, prompting the Board to grant an adverse judgment and terminate the proceeding.
Integrated DNA Technologies, Inc. et al. v.Tecan Group AG
The PTAB granted institution for an IPR challenging claims 1-16 of a nucleic acid analysis patent, finding reasonable likelihood of success. The Board rejected the Patent Owner's motion to deny based on prior art similarity, allowing the technical merits of anticipation and obviousness over Kivioja and Bielas to proceed to trial.
Illumina, Inc. v.Molecular Loop Biosciences, Inc.
The PTAB upheld the patentability of claims 1-9 for Molecular Loop Biosciences against Illumina. The Board rejected all grounds of anticipation and obviousness over prior art like Chee, finding that the required 'collapsing step' necessitates combining both target sequence and differentiator tag information.
Biofrontera Incorporated et al. v.Sun Pharmaceutical Industries, Inc.
The PTAB found all challenged claims unpatentable by a preponderance of the evidence. The Petitioner successfully argued that combining prior art references (Lundahl and Larsen) rendered the illuminator system obvious to a Person Having Ordinary Skill in the Art (POSITA).
Facing a similar IP matter?
Arctic Invent is a specialist IP firm with deep litigation expertise across India, EU, US, and UK. Our team uses data-driven strategy to build stronger cases.